Back to mobile site

More on RVMD

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-46.0% Growth)
- Ratings (9.6 Score)

Upcoming Events

- Earnings (11/11/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Revolution Medicines (NQ:RVMD)
Delayed: 187.69 -6.59 (3.39%)
Prev. Close $194.28  
Open$192.06 
52 Wk High$ 
52 Wk Low$ 
Day High$194.59 
Day Low$185.34 
P/E N/A  
EPS$ 
Volume1,487,200 

Friends, Peers and Foes (?): MRK, ABBV, ERAS, ONC, EYPT (more...)

Oct 21, 2026 04:05 PM Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
Oct 20, 2026 08:01 AM Revolution Medicines starts Phase 3 trial of zoldonrasib for lung cancer
Oct 20, 2026 08:01 AM Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastati
Oct 19, 2026 07:19 AM Revolution (RVMD) PT Raised to $241 at Truist Securities; 'Longer-Term Thesis Holds Firm'
Oct 16, 2026 07:54 AM Guggenheim Reiterates Buy Rating on Revolution (RVMD)
Oct 16, 2026 06:23 AM Jefferies Highlights Top Mid-Cap Biotech Stocks Ahead of Earnings
Oct 16, 2026 02:51 AM William Blair Starts Revolution (RVMD) at Outperform
Oct 15, 2026 09:46 AM Revolution Medicines' daraxonrasib gets positive EU panel opinion
Oct 15, 2026 09:45 AM Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Oct 14, 2026 08:57 AM Revolution (RVMD) PT Raised to $260 at RBC Capital
View All Articles

Entities mentioned with RVMD

View All Entities